Eli Lilly and Company announces first Lilly Gateway Labs facility in San Diego for 2024

In a strategic move to strengthen its position in the life sciences sector, Eli Lilly and Company (NYSE: LLY) has revealed plans to inaugurate its first-ever Lilly Gateway Labs facility in San Diego, California, in the first half of 2024. This initiative marks the company’s third such facility, joining its existing sites in San Francisco and Boston.

Lilly Gateway Labs facility : A Hub for Biotech Innovation and Collaboration

Daniel Skovronsky, chief scientific officer, and president, Lilly Research Laboratories, expressed enthusiasm for the expansion. “San Diego’s dynamic life sciences community makes it an ideal location for our new Gateway Labs,” he said. “Our aim is to foster a nurturing environment for scientific discovery by providing access to our expertise and resources.”

Lilly Gateway Labs is designed as a shared innovation accelerator, offering participants not just cutting-edge lab space but also unique exposure to Lilly’s vast scientific and functional knowledge. This model fosters an ecosystem of collaboration and learning, where companies can engage with Lilly’s experts and potentially receive financial investments.

Eli Lilly expands life sciences footprint with Lilly Gateway Labs facility in San Diego

Strategic Partnership and Operational Excellence

In collaboration with Alexandria Real Estate Equities Inc. (ARE), the new Lilly Gateway Labs facility is set to be a state-of-the-art center combining Lilly’s scientific prowess with ARE’s operational expertise. Located in Alexandria’s University Town Center (UTC) campus, the site will offer about 62,000 square feet of adaptable lab space and open workstations. It’s anticipated to house 10 companies and over 120 biotech and Lilly employees, creating a vibrant community for scientific exchange.

Julie Gilmore, vice president, and global head of Gateway Labs, highlighted the importance of such initiatives. “Our Gateway Labs have been pivotal in nurturing early-phase external innovation,” she noted. “The expansion in San Diego is a testament to our commitment to enabling scientific breakthroughs through collaboration and mentorship.”

With this new development, Eli Lilly and Company continues to underscore its role as a leader in fostering innovation in the biotech sector, contributing significantly to the advancement of life sciences research.